Objective To develop recommendations for cardiovascular risk (CVR) management in gout,
vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD) …

Background and objectives The optimization of immunosuppressive therapies has led to a
marked improvement in the survival of ANCA-associated vasculitides (AAV). The main issue …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are small-vessel
vasculitides that include granulomatosis with polyangiitis (formerly Wegener's …

Background Because anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis
(AAV) is a rare, life-threatening, auto-immune disease, conducting research is difficult but …

Despite improvement in the prognosis of ANCA-associated vasculitides (AAVs), increased
mortality, mainly from a cardiovascular origin, persists. We aimed to determine the role of …

Objectives ANCA-associated vasculitis (AAV) has been associated with increased risk of
cardiovascular (CV) events. The aim was to assess traditional and disease-related CV risk …

Objective To investigate the occurrence of cardiovascular events (CVEs) in a large cohort of
patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) across …

Objectives Patients with ANCA-associated vasculitis are at increased risk of cardiovascular
events. The aim of the present study was to assess predictors of cardiovascular events in …

Objective To investigate the occurrence of cardiovascular events (CVEs) in a large cohort of
patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) across …